NPO

252.8704.15%
AM

Adele M. Gulfo

Independent Director

Ms. Adele M. Gulfo, M.B.A., is Member of Strategic Advisory Board of Indegene Limited. Ms. Gulfo is Independent Director of NewAmsterdam Pharma Company N.V. from April 2025. Ms. Gulfo is Independent Director of Tyra Biosciences, Inc. from January 29, 2025. She was Chief Executive Officer of Biopharma Commercial Unit of Sumitomo Pharma America, Inc. from July 2023 to September 2024 and had been its Director from 2024 until 2024. Ms. Gulfo was Chief Business and Commercial Development Officer at Sumitovant Biopharma Ltd. She served as an CEO of Biopharma Commercial Unit of Sumitomo Pharma America, Inc. at Sumitomo Pharma Co. Ltd. since 2023 until October 2024 and served as its Executive Officer since July 01, 2023 until October 2024. She is Director at Myovant Sciences Ltd. since December 27, 2019 and served as an Interim Chief Commercial Officer since May 11, 2020 until April 2021. She served as Chief of Commercial Development at Roivant Sciences Ltd since May 2018 until December 2019. Ms. Gulfo joined Roivant Sciences in May 2018. She has been Independent Director at Enpro Inc. (formerly known as EnPro Industries, Inc.) since October 30, 2018. She had been Independent Director at Medexus Pharmaceuticals Inc. since June 25, 2019 until 2023. She served as an Executive Vice President of Global Collaboration and Strategic Operations at Mylan, Inc. since January 8, 2014 until January 2018. Ms. Gulfo served as Chief Strategy Officer of Mylan N. V. since 2014 until January 2018. Previously, Ms. Gulfo held leadership positions at AstraZeneca Pharmaceuticals, Parke-Davis (Division of Warner-Lambert), SpectraTech Inc. and Fischer Scientific. Ms. Gulfo served as the President and General Manager, Latin America of Pfizer Inc from 2012 to 2014. She served as President of US Primary care business at Pfizer Inc. She served as Vice President of Healthcare Innovation and Corporate Strategy at AstraZeneca PLC. She joined Pfizer from AstraZeneca, where she served as Vice President of Business Development and Design for launch, responsible for sourcing, evaluating and securing external assets including Partnerships, acquisitions and licenses, as well as clinical and commercial development across all therapeutic areas of products entering Phase IIb. She serves as Member of Industrial Advisory Board at Cleveland Clinic Innovations. She serves as Regional President, of Latin America in Pfizer's Emerging Markets Business Unit In this capacity, she leads a team of over 4,000 colleagues operating across more than 23 countries. She served as President and General Manager of Pfizer's U. S. Primary Care Business Unit, which included the managed markets (corporate and government customer) organization for all of Pfizer's Biopharmaceutical Business Units from 2009 to 2012. Prior to joining Pfizer, she served as Vice President of Business Development, Innovation and Design for Launch at Astra-Zeneca Pharmaceuticals. She served positions of increasing responsibility at Warner-Lambert, including Senior Director of cardiovascular marketing. Prior to launch, she developed the market with award-winning medical and public education that helped to establish the significance of lowering cholesterol in preventing and managing heart disease. Partners included the American Heart Association, the National Institutes of Health and leading academic institutions. She is trained as a scientist with experience in both operational and strategic roles; she serves as a Member of the Board of Directors for the Cleveland Clinic's Global Cardiovascular Innovation Center. Ms. Gulfo was an Independent Director of Bemis Company, Inc. since June 23, 2015 until June 11, 2018. She serves as a Director of Volunteers of America – Greater New York, Inc from 2012 to 2018. She has been awarded five U. S. Patents for innovative packaging designed to help patients adhere to their medicines. She frequently speaks at leading industry and business conferences including The Wall Street Journal's Women in the Economy: An Executive Task Force conference and has been featured in Fortune, Forbes, BusinessWeek and the Wall Street Journal. She is a Member of the C200 – the pre-eminent organization of women business leaders, the National Association of Female Executives and the Healthcare Businesswomen's Association's Advisory Board. She is especially proud of receiving the 2012 C200 Luminary Award for Corporate Entrepreneurship. She launched LIPITOR in 1997 to become the world’s best-selling medicine. She holds eight patents. She has also held various leadership roles with global public companies, giving her valuable strategic experience and perspective in understanding global challenges and opportunities. She served as Chief Business and Commercial Development Officer at Sumitovant Biopharma, Inc and a subsidiary of Sumitovant, since December 2019. Ms. Gulfo also serves on the Innovation Growth Board for Partners Healthcare and is an advisor for Springboard Life Sciences. She is a member of the Innovation Growth Board at Mass General Brigham, the largest hospital-based research enterprise in the United States and serves as a director of Battelle Memorial Institute, an independent, non-profit applied science and technology research organization. Ms. Gulfo received a BS in biology from Seton Hall University and an MBA in marketing with highest honors from Fairleigh Dickinson University. She studied post-graduate molecular biology at the University of Medicine and Dentistry of New Jersey where she began her career.

Positions